Toremifene
Hormonal / PCTAlso known as: Fareston, Toremifene Citrate
Mechanism
Toremifene is a chlorinated derivative of tamoxifen FDA-approved for metastatic breast cancer. It has a similar mechanism to tamoxifen but with a potentially improved safety profile — it shows less DNA adduct formation (a marker of genotoxicity) and reduced endometrial cancer risk. It is sometimes used as a tamoxifen alternative for PCT.
Technical detail
Toremifene is a first-generation triphenylethylene SERM structurally identical to tamoxifen except for a chlorine substitution at position 4. This modification reduces the formation of reactive metabolite intermediates and DNA adducts associated with tamoxifen's genotoxic potential. It demonstrates equivalent ER antagonism in breast tissue, similar bone-protective partial agonism, but reduced uterotrophic activity and endometrial carcinoma risk compared to tamoxifen. It blocks hypothalamic-pituitary ER negative feedback similar to tamoxifen, supporting its off-label use in PCT protocols.
Evidence
- strong
Smith et al. (2013) — The Journal of Urology — PMID: 23234631
Among 1,284 men receiving androgen deprivation therapy, toremifene reduced new vertebral fractures from 4.9 percent to 2.5 percent over two years and also improved bone mineral density and lipid markers, supporting bone-protective use in this setting.